Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Products under Development by Stage of Development | 7 | 1 |
| Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Products under Development by Therapy Area | 8 | 1 |
| Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Products under Development by Indication | 9 | 1 |
| Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Pipeline Products Glance | 10 | 1 |
| Early Stage Products | 10 | 1 |
| Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Products under Development by Companies | 11 | 2 |
| Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Products under Development by Universities/Institutes | 13 | 2 |
| Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Therapeutics Assessment | 15 | 5 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 1 |
| Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Companies Involved in Therapeutics Development | 20 | 2 |
| Anacor Pharmaceuticals, Inc. | 20 | 1 |
| Astex Pharmaceuticals, Inc. | 21 | 1 |
| Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Drug Profiles | 22 | 7 |
| AN-3485 Drug Profile | 22 | 1 |
| AT-13148 Drug Profile | 23 | 2 |
| Small Molecules to Inhibit Rho-Associated Kinase I for Oncology Drug Profile | 25 | 1 |
| Small Molecules to Inhibit ROCK1 for Breast Cancer Drug Profile | 26 | 1 |
| Small Molecules to Inhibit ROCK1 for Cancer Drug Profile | 27 | 1 |
| TRN-101 Drug Profile | 28 | 1 |
| Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Dormant Projects | 29 | 1 |
| Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Discontinued Products | 30 | 1 |
| Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Featured News &Press Releases | 31 | 4 |
| Jun 18, 2013: Moffitt Cancer Center Announces Strategic Partnership with Advinus Therapeutics | 31 | 1 |
| Jan 17, 2013: Cancer Research UK And Cancer Research Technology Launches Phase I Clinical Trial With AT13148 To Treat Several Cancer Types | 31 | 2 |
| Jan 16, 2013: Astex Pharma Announces Cancer Research UK And Cancer Research Technology Initiate AT13148 Clinical Trial To Treat Several Cancer Types | 33 | 1 |
| Jul 10, 2012: Experimental Drug Could Treat Different Cancers, New Research Says | 33 | 1 |
| Oct 18, 2007: Astex Drug Candidates To Be Featured At The 2007 AACR-NCI-EORTC International Conference | 34 | 1 |
| Appendix | 35 | 2 |
| Methodology | 35 | 1 |
| Coverage | 35 | 1 |
| Secondary Research | 35 | 1 |
| Primary Research | 35 | 1 |
| Expert Panel Validation | 35 | 1 |
| Contact Us | 35 | 1 |
| Disclaimer | 36 | 1 |